沙美特罗替卡松粉吸入剂治疗中重度儿童哮喘38例疗效观察

目的:观察沙美特罗替卡松粉吸入剂治疗儿童哮喘的疗效.方法:38例患儿,给予沙美特罗替卡松粉吸入,50μg/100μg/次,每日2次.观察治疗前、治疗1月、3月的呼气峰流速值(PEF)及其占个人预计值的百分比;记录治疗第1月、3月时按需使用短效β2 受体激动剂的天数;记录治疗前后病人的主观感受及治疗过程中的不良事件.结果:治疗前患儿PEF值占预计值的百分比与治疗1月后比较差异有统计学意义,治疗3月与治疗前及治疗1月时相比差异亦有统计学意义.治疗第1月按需使用短效β2 受体激动剂的天数与第3月相比差异有统计学意义(P<0.01).治疗3月后病人主观感受明显好转占89.5%,无加重及恶化病人.治疗过程中有3例出现轻微不良反应.结论:沙美特罗替卡松粉吸入治疗儿童中重度哮喘,能够有效控制症状,减少短效β2受体激动剂的使用,显著提高哮喘患者的生活质量,不良反应小.     

慢性阻塞性肺疾病患者使用沙美特罗氟替卡松粉吸入剂的护理干预

目的:探讨护理干预对慢性阻塞性肺疾病患者使用沙美特罗氟替卡松粉吸入剂的影响。方法:选择236例使用沙美特罗氟替卡松粉吸入剂的慢性阻塞性肺疾病患者实施护理干预,比较分析护理干预前后患者沙美特罗氟替卡松粉吸入剂使用的认同率、正确操作率以及出错情况。结果:护理干预后患者对沙美特罗氟替卡松粉吸入剂使用的认同率、正确操作率明显提高(P<0.05),出错的人数较护理干预前明显减少(P<0.05)。结论:护理干预可以明显提高慢性阻塞性肺疾病患者对沙美特罗氟替卡松粉吸入剂重要性的认识,使患者能够更加积极主动地掌握正确的使用方法,提高临床疗效。     

0．05％丙酸氟替卡松乳膏治疗湿疹的临床疗效观察

目的：观察0．05％丙酸氟替卡松乳膏治疗湿疹的临床疗效。方法：将我院收治的55例湿疹患者随机分为两组,观察组28例患者采用0．05％丙酸氟替卡松乳膏治疗,对照组27例患者采用0．1％丁酸氢化可的松软膏治疗,比较分析两组的疗效。结果：观察组总有效率为92．9％,对照组为66．7％,两组问有显著性差异（χ2=5．8928,P〈0．05）,两组均无明显不良反应发生。结论：0．05％丙酸氟替卡松乳膏治疗湿疹疗效满意,且不良反应少,值得临床关注。     

沙美特罗/丙酸氟替卡松干粉剂吸入治疗成人支气管哮喘60例疗效观察

目的:探讨沙美特罗/丙酸氟替卡松干粉剂(商品名:舒利迭,葛兰素史克公司出品)吸入治疗支气管哮喘的疗效。方法:90例患者随机分为2组,治疗组采用沙美特罗/丙酸氟替卡松干粉剂50/250"g每日2次吸入,对照组采用丙酸氟替卡松气雾剂(商品名:辅舒酮,葛兰素史克公司出品)250"g每日2次吸入,治疗第4、8周两次评价患者哮喘症状和疗效。结果:在治疗第4、8周,治疗组哮喘症状和对照组相比明显减轻。结论:舒利迭为沙美特罗/丙酸氟替卡松混合吸入剂,是控制哮喘的一个良好选择。     

氟替卡松在慢性鼻窦炎内窥镜术后的应用

目的明确慢性鼻窦炎内窥镜术后使用氟替卡松能否提高局部的抗炎作用、有助于粘膜的恢复、防止或延缓息肉的复发。方法采取随机地的方法将鼻内窥镜手术后到门诊随访的慢性鼻窦炎Ⅱ、Ⅲ型患者 4 0例分入试验组和对照组 ,试验组给予氟替卡松喷鼻 ,对照组为空白对照 ,随访三个月 ,比较两组术后临床症状鼻塞、流脓涕及体征鼻腔粘连、术腔粘膜水肿、窦口开放的恢复程度有无差异。结果慢性鼻窦炎内窥镜术后的鼻塞、流脓涕、鼻腔粘连的恢复程度 ,在试验组与对照组之间差异无显著性 (P >0 .0 5 ) ,但术腔粘膜水肿、窦口开放的恢复程度 ,在试验组明显优于对照组 (P <0 .0 1)结论慢性鼻窦炎内窥镜术后的鼻腔清理非常重要 ,结合使用氟替卡松能明显减轻术腔粘膜水肿、使窦口开放良好 ,说明氟替卡松在慢性鼻窦炎内窥镜术后对增加局部抗炎、促进粘膜恢复、防止或延缓息肉的复发有重要作用。     

A placebo controlled trial of fluticasone propionate in asthmatic children

Fluticasone propionate is a synthetic steroid for use by the inhaled route. It's high topical potency and low systemic bioavailability make it suitable for use in asthmatic children. A total of 258 children were randomised in a double-blind study to receive fluticasone propionate (50 g bd) as the dry powder formulation inhaled via a Diskhaler inhaler, or matched placebo (with current therapy) for 4 weeks throughout which time diary cards were completed. During clinic visits lung function and adrenal function were measured. Fluticasone propionate produced a significantly greater increase in morning peak expiratory flow rate (PEFR) (adjusted mean difference over days 1–28, 17 l/min (95% CI; 10, 24);P<0.001) and evening PEFR (adjusted mean difference over days 1–28, 16 l/min (95% CI; 9, 23);P<0.001). In addition, diary card symptom scores, beta₂-agonist rescue and clinic lung function improved significantly on fluticasone propionate. There were few adverse events and basal plasma cortisol remained within the normal range. In conclusion fluticasone propionate at 50 g bd is superior to placebo (current therapy) in the treatment of childhood asthma with no evidence of adverse effects.     

中药结合氟替卡松鼻喷剂治疗小儿过敏性鼻炎

目的:探讨中药结合氟替卡松鼻喷剂治疗小儿过敏性鼻炎的临床疗效观察。方法:将198例过敏性鼻炎患儿随机分为西药组、中药组、观察组,各66例,西药组给予氟替卡松鼻喷剂治疗;中药组给予自拟中药汤剂治疗;观察组给予氟替卡松鼻喷剂联合自拟中药汤剂治疗。结果:西药组与中药组疗效总有效率相近,差异比较无统计学意义(P0.05);观察组疗效总有效率明显优于西药组和中药组,差异比较均有统计学意义(P0.05)。结论:应用中药结合氟替卡松鼻喷剂治疗小儿过敏性鼻炎疗效显著,具有安全可靠、复发率低、不良反应少等优点,值得临床推广。     

Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone

ABSTRACT

Objective: This long-term prospective study was conducted in African Americans with persistent asthma to examine the safety and effectiveness of the combination of the inhaled corticosteroid, fluticasone propionate (FP), and the long-acting beta-agonist, salmeterol, compared with FP alone.

Research and design methods: This was a randomized, double-blind, parallel group, multi-center trial in adolescent and adult subjects ≥12 years of age symptomatic on a low dose of an inhaled corticosteroid (ICS). The study consisted of a 2-week screening period on low dose ICS; a 4-week open-label FP 250?mcg twice daily (BID) run-in; a 52-week double-blind period (FP/salmeterol [FSC] 100/50?mcg [n = 239] or FP 100?mcg [n = 236] BID), and a 4-week FP 250?mcg BID run-out period. Annualized exacerbation rate was the primary outcome for comparing the two treatments. Other measures of asthma control included peak expiratory flow, asthma symptoms, and albuterol use. Safety was assessed through adverse events.

Results: Exacerbation rates were not significantly different in those treated with FSC 100/50?mcg (0.449 per year) compared with FP 100?mcg (0.529 per year, p = 0.169). When the per-protocol analysis was applied, the rates were 0.465 and 0.769 per year for FSC 100/50?mcg and FP 100?mcg, respectively. Treatment with FSC 100/50?mcg provided statistically greater improvements in lung function measures and nighttime awakenings (p ≤ 0.050) and demonstrated numerically lower daily symptoms (p = 0.216) and albuterol use (p = 0.122). Two subjects treated with FSC 100/50?mcg were hospitalized for an asthma exacerbation compared to three treated with FP 100?mcg. The overall incidence of adverse effects during double-blind treatment was similar between the FSC 100/50?mcg and FP 100?mcg treatment groups (61?%?and 68?%?, respectively). Frequent study visits were required of subjects during this long-term study, and it remains unknown whether this intervention may affect generalizability.

Conclusion: In this large, prospective study among African Americans with asthma, the addition of salmeterol to FP resulted in a similar low rate of exacerbations and improved other markers of asthma control. Both FSC 100/50?mcg and FP 100?mcg were well-tolerated, and the overall safety-profiles were similar over 1 year of treatment.     

Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial

Abstract

Objective:

To demonstrate the efficacy and safety of fluticasone propionate/formoterol fumarate (flutiform) in a pressurised metered-dose inhaler (pMDI) compared to two formulations of the fluticasone propionate component (Skyepharma fluticasone [SKP FP] or Flovent, GlaxoSmithKline [GSK FP]) in adults and adolescents with moderate-to-severe asthma.